CT study in senile dementia of Alzheimer type
โ Scribed by Kenichi Ueyama; Hiroshi Fukuzako; Tsuyoshi Fukuzako; Yoshirou Hokazono; Kouzou Takeuchi; Tomo Hashiguchi; Morikuni Takigawa; Takao Yamanaka; Kei Matsumoto
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 419 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
โฆ Synopsis
We evaluated 14 patients with senile dementia of Alzheimer type (SDAT) and 15 age-matched normal elderly controls using psychological tests and computed tomography scans. The low-density rate (LDR) was used as an index of brain atrophy. SDAT patients had significantly higher scores on the Hasegawa Dementia Scale (p < 0.01) and significantly lower scores on the Bender Gestalt Test (p < 0.01) than control subjects. The LDRs of the left and right hemispheres were significantly higher in the SDAT group than in the control group in all three slices investigated (p < 0.05/6 = 0.0083). In the control group, the LDR was higher in the left hemisphere than in the right hemisphere in one slice 0, < 0.05/6 = 0.0083). In SDAT patients, significant diagnosis by hemisphere interaction was observed in one slice (p < 0.05), with higher LDR on the left than on the right (p < 0.05/6 = 0.0083). Our findings suggest that cortical atrophy is predominant on the left side in patients with SDAT.
KEY worm-Senile dementia of Alzheimer type, CT, brain atrophy, asymmetry, cognitive impairment.
๐ SIMILAR VOLUMES
Objective. The main hypothesis was that subtle vitamin B12 deยฎciencies occur more commonly in senile dementia of Alzheimer type (SDAT) than in healthy elderly individuals, and may be revealed by elevated total serum homocysteine (tHcy). A subsidiary hypothesis was that such deยฎciencies would be nutr
Milacemide, both an MAO-B inhibitor and a prodrug for glycine, has demonstrated cognitive enhancing effects in animal models, in cognitively intact young and elderly, and has been suggested as a potential treatment for senile dementia of the Alzheimer type (SDAT). This multicenter open-label trial e
Acetylcholinesterase (AChE) activity was measured in cerebrospinal fluid (CSF) samples from 36 individuals, including 12 persons with Alzheimer's disease, 12 normal controls, and 12 patients with other dementias. AChE activity also was measured in 47 normal subjects whose ages ranged from 20 to 84 t
## Abstract Patients suffering from senile dementia of Alzheimer type, elderly patients suffering from functional psychiatric illness and younger functionally ill patients were tested using a battery of ageing measures. Although the younger group was clearly different from the older groups, there w